Court Refuses Ranbaxy Rehearing Bid In Lipitor Case

Law360, New York (October 23, 2006, 12:00 AM EDT) -- Ending another chapter in Pfizer Inc. and Ranbaxy Laboratories’ protracted battle over a generic version of blockbuster cholesterol drug Lipitor, an appeals court on Monday denied Ranbaxy’s petition for rehearing a decision in favor of Pfizer.

The U.S. Court of Appeals for the Federal Circuit issued a mixed ruling in the long-running battle over Lipitor, the world’s best-selling drug, on August 2.

The Federal Circuit’s ruling affirmed a lower court’s decision that one Pfizer patent covering the drug was valid, but struck down a second Lipitor-related...
To view the full article, register now.